Merck & Co (MRK)
$81.75 1.44 (1.79%)
9:16 EDT MRK Stock Quote Delayed 20 Minutes
Previous Close $80.31
Market Cap 219.93B
PE Ratio 140.95
Volume (Avg. Vol.) 14,067
Day's Range 80.31 - 80.31
52-Week Range 65.25 - 92.64
Dividend & Yield 1.92 (2.35%)
MRK Stock Predictions, Articles, and Merck & Co News
- From InvestorPlace
- From the Web
Friday was a down day, but four of the past five have been up days for the Dow and it's worth pointing out that after one of the most rapid corrections/bear markets on record, plenty of bad news is already being consumed, but plenty of uncertainty lingers, too.
Stocks popped Friday as investors sought coronavirus clarity from the White House and speculated the Fed could cut rates to zero.
Tuesday's 3 big stock charts feature suddenly unloved names that have traded back to past lows — and thus need support to hold.
Merck's proposed spinoff of women's health and other prescription drug businesses looks to boost growth and upside for MRK stock.
Merck stock fell on news it will spin off slow-growth areas to focus on Keytruda, its anti-cancer immunotherapy blockbuster.
Merck (MRK) earnings for the healthcare company's fourth quarter of 2019 have MRK stock down Wednesday on major spin-off news.
These healthcare stocks are worth selling now as Sanders rises in the polls and given his stance that prices should be cut in half.
FDA approval of Vascepa in use for cardiovascular events just widened Amarin’s revenue potential. Amarin stock should have a banner 2020.
Though the market is at all-time highs, not every stock can say the same. These three stocks to buy should reach new peaks in 2020.
Some solid consumer sentiment and spending reports boosted stocks to close the week, although gains were modest.
Thursday's 3 big stock charts highlight 3 recent movers that could rally if broad market optimism continues.
Some of today's malaise can be attributed to Alphabet (NASDAQ:GOOGL,GOOG), which declined following a disappointing earnings report issued yesterday after the market closed. The internet search giant reported earnings of $10.12 a share on revenue of $40.50 billion while analysts expected earnings of $12.42 on revenue of $40.32 billion.
With FDA Breakthrough Therapy designations and robust drug pipelines, these biotech companies are all stocks to buy for 2020.
A divided Federal Reserve is a new issue for investors to consider. Read more about what happened in the Dow Jones today.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader